Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Wednesday: Microsoft Corporation (NASDAQ:MSFT), Cisco Systems, Inc (NASDAQ:CSCO), Lumber Liquidators Holdings Inc (NYSE:LL), Zogenix, Inc (NASDAQ:ZGNX)
- Microsoft Corporation (NASDAQ:MSFT), with shares declined -0.02% is now trading at $42.02. The Stock is active as 12.08M shares changed hands versus its average volume of 42.40M shares.
- Cisco Systems, Inc (NASDAQ:CSCO), with shares declined -0.99% is now trading at $28.38. The Stock is active as 10.92M shares changed hands versus its average volume of 31.88M shares.
- Lumber Liquidators Holdings Inc (NYSE:LL) with shares enhanced 13.86% is now trading at $33.68. The Stock is active as 11.43M shares changed hands versus its average volume of 4.87M shares.
- Zogenix, Inc (NASDAQ:ZGNX), with shares dipped -27.75% is now trading at $1.24. The Stock is active as 23.67M shares changed hands versus its average volume of 3.50M shares.
Latest NEWS regarding these Stocks are depicted underneath:
Microsoft Corporation (NASDAQ:MSFT)
Microsoft Corporation (MSFT), on Monday declared that its board of directors declared a quarterly dividend of $0.31 per share. The dividend is payable June 11, 2015, to shareholders of record on May 21, 2015. The ex-dividend date will be May 19, 2015.
Founded in 1975, Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The corporation’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Cisco Systems, Inc. (NASDAQ:CSCO)
Cisco Systems, Inc. (CSCO), declared an extension of its cloud and data center relationship with Microsoft to comprise a new technology platform designed to accelerate service delivery and streamline the journey to the Intercloud for cloud providers.
Today’s next-generation cloud services require close compatibility between hardware, software, network, storage, and compute. As a result, cloud providers are challenged with managing the complexity and cost of integrating the infrastructure and application layers required to bring new cloud services to market. To address these issues, Cisco and Microsoft are launching the Cisco Cloud Architecture for the Microsoft Cloud Platform — an integrated solution that combines Windows Azure Pack and Cisco Application Centric Infrastructure (Cisco ACI) to assist cloud providers rapidly deliver hybrid cloud services while drastically simplifying operations and reducing costs.
Additionally, 14 cloud providers recently declared they plan to join Cisco’s Intercloud partner ecosystem, bringing the number of Intercloud providers to more than 60 with a footprint of more than 350 data centers across 50 countries.
Nick Earle, senior vice president, Cloud and Managed Services, Cisco:
“We want our service provider partners to move up-market with us and offer higher-end cloud services. By partnering with Microsoft we’re able to deliver a tightly integrated, application centric cloud architecture. This unique new platform will assist our partners dramatically accelerate the delivery of new and innovative hybrid cloud services for their customers.”
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide.
Lumber Liquidators Holdings, Inc. (NYSE:LL)
Lumber Liquidators Holdings, Inc. (LL), the largest specialty retailer of hardwood flooring in North America, recently declared an agenda for its business update conference call to be held on March 12, 2015 at 10:00 a.m. Eastern Time. The conference call will be accompanied by a slide presentation that will be accessible by about 7:00 a.m. on the morning of the call.
Lumber Liquidators Holdings, Inc., together with its auxiliaries, operates as a multi-channel specialty retailer of hardwood flooring, and hardwood flooring enhancements and accessories.
Zogenix, Inc. (NASDAQ:ZGNX)
Zogenix, Inc. (ZGNX), a pharmaceutical corporation developing and commercializing products for the treatment of central nervous system (CNS) disorders, stated financial results for the fourth quarter ended December 31, 2014.
Fourth Quarter and Full Year 2014 Financial Results:
Total proceeds for the fourth quarter 2014, which comprised of net product proceed, contract manufacturing proceed, and service and other proceed, were $14.9 million, up 50% from $9.9 million in the fourth quarter 2013.
Net product proceed for the fourth quarter 2014 was $5.0 million, contrast to $9.0 million in the fourth quarter 2013. The Corporation launched Zohydro ER in March 2014, with proceed recognized based on product dispensed through patient prescriptions as estimated by Source Healthcare Analytics. The fourth quarter 2013 net product proceed comprised of sales from the SUMAVEL DosePro business, which the Corporation sold in May 2014 to Endo International plc (Endo).
As of December 31, 2014, the Corporation had $7.1 million in deferred proceed for Zohydro ER sold to wholesalers but not yet dispensed through patient prescriptions. Gross-to-net sales deductions will be recorded at the time the prescription units are dispensed.
Contract manufacturing proceed on SUMAVEL DosePro supplied to Endo under the companies’ supply contract for the fourth quarter 2014 was $8.9 million.
Service and other proceed for the fourth quarter 2014 was $930,000, contrast to $915,000 in the fourth quarter 2013, and was primarily comprised of fees from Valeant Pharmaceuticals for the Corporation’s co-promotion of Migranal(R) Nasal Spray, which began in August 2013.
Total proceeds for the full year 2014 were $40.5 million, up 23% from $33.0 million in the full year 2013. Net product proceed for the full year 2014 was $21.7 million, contrast to $31.7 million in the full year 2013. Contract manufacturing proceed for the full year 2014 was $15.4 million. Service and other proceed for the full year 2014 was $3.4 million, contrast to $1.3 million in the full year 2013.
Zogenix, Inc., a pharmaceutical corporation, develops and commercializes therapies for the treatment of central nervous system disorders and pain. The corporation’s commercial product comprises Zohydro, a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
